eligibility_summary
Inclusion: Adults ≥18, ECOG ≤2, untreated FL grade 1–3a needing therapy (GELF), measurable disease, ANC ≥1,000 (≥500 if BM+), platelets ≥50k (≥25k if BM+), bilirubin ≤2×ULN, AST/ALT ≤2.5×ULN, CrCl ≥45 or Cr <1.5, negative pregnancy test, effective contraception, Revlimid REMS. Exclusion: prior systemic therapy (limited RT ≥4 wks ok), other trials, live vaccines, CNS disease, grade 3b/transformed FL, uncontrolled infection, ALC >5k, active HBV/HCV/HIV (controlled HIV ok), significant CVD, pregnancy/breastfeeding, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm immunotherapy trial in previously untreated follicular lymphoma testing: 1) Epcoritamab-bysp (Epkinly): a subcutaneous, full-length bispecific T‑cell–engaging monoclonal antibody (CD3×CD20). Mechanism: simultaneously binds CD20 on malignant B cells and CD3 on T cells to form an immune synapse, activate T cells, and induce targeted cytotoxic killing of CD20+ FL cells. 2) Lenalidomide (Revlimid): an oral immunomodulatory drug (IMiD). Mechanism: binds cereblon E3 ligase to degrade IKZF1/3, enhancing T- and NK-cell activation, modulating cytokines, and inhibiting angiogenesis, thereby augmenting anti-tumor immunity. Targets/pathways: CD20+ B cells, CD3+ T-cell activation, cereblon–IKZF pathway, T/NK effector function, tumor angiogenesis, MRD and T-cell balance explored.